Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
NCT00219596
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- patients with open-angle glaucoma or ocular hypertension
- closed/barely open anterior chamber angle or a history of acute angel closure glaucoma
- Ocular surgery within 3 months
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Hellerup,
- Vejle,
- Oulu,
- Bergen,
- Oslo,
- Trondheim,
- Gothenburg,
- Huddinge,
- Linkoping,
- Lund,
- Malmo,
- Umea,
- Uppsala,
- Birmingham, Alabama
- Flagstaff, Arizona
- Artesia, California
- Los Angeles, California
- Newport Beach, California
- Sacramento, California
- San Francisco, California
- Colorado Springs, Colorado
- Gainesville, Florida
- Lecanto, Florida
- Miami, Florida
- Panama City, Florida
- Idaho Falls, Idaho
- Bourbonnais, Illinois
- Calumet City, Illinois
- Chicago, Illinois
- Chicago, Illinois
- Evansville, Indiana
- Madison, Indiana
- New Albany, Indiana
- Newburgh, Indiana
- Iowa City, Iowa
- Wichita, Kansas
- Louisville, Kentucky
- Bangor, Maine
- Reading, Massachusetts
- Ann Arbor, Michigan
- Detroit, Michigan
- Stillwater, Minnesota
- Creve Coeur, Missouri
- Kansas City, Missouri
- Warrensburg, Missouri
- Washington, Missouri
- Piscataway, New Jersey
- Princeton, New Jersey
- Brooklyn, New York
- New York, New York
- Rochester, New York
- Durham, North Carolina
- Durham, North Carolina
- Greensboro, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Roseburg, Oregon
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Reading, Pennsylvania
- Wyomissing, Pennsylvania
- Charleston, South Carolina
- Charleston, South Carolina
- Maryville, Tennessee
- Austin, Texas
- Austin, Texas
- Dallas, Texas
- El Paso, Texas
- El Paso, Texas
- Fort Worth, Texas
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- Fredericksburg, Virginia
- Seattle, Washington
- Beijing, Beijing
- Beijing, Beijing
- Guangzhou, Guangdong
- Shanghai, Shanghai
- Xi?an, Shanxi
- Hangzhou, Zhejiang
- Hangzhou, Zhejiang
- Shanghai,
- Caen,
- Clermont-ferrand,
- Lyon,
- Marseille Cedex 05,
- Saint Herblain,
- Darmstadt,
- Darmstadt,
- Landau / Pfalz,
- Regenstauf,
- Schorndorf,
- Starnberg,
- Heraklion, Crete
- Thessaloniki, Macedonia
- Alexandroupoli,
- Larisa,
- Chieti,
- Foggia,
- Genova,
- Milano,
- Monza (MI),
- Pisa,
- Malmo,
- Molndal,
- Sundsvall,
- örebro,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension | |||
Official Title ICMJE | An 8-Week, Randomized, Open-Label, Parallel Group Study Comparing The Efficacy And Safety Of Xalacom With The Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension | |||
Brief Summary | to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE | Not Provided | |||
Publications * | Zhao JL, Ge J, Li XX, Li YM, Sheng YH, Sun NX, Sun XH, Yao K, Zhong Z; Xalacom Study Group in China. Comparative efficacy and safety of the fixed versus unfixed combination of latanoprost and timolol in Chinese patients with open-angle glaucoma or ocular hypertension. BMC Ophthalmol. 2011 Aug 19;11:23. doi: 10.1186/1471-2415-11-23. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 240 | |||
Original Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | September 2006 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | China | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00219596 | |||
Other Study ID Numbers ICMJE | A6641028 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. ) | |||
Study Sponsor ICMJE | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | November 2006 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |